QR-Code

Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy Participants

ABSTRACT Aficamten is a next‐in‐class, small‐molecule, cardiac myosin inhibitor in development for treating hypertrophic cardiomyopathy (HCM). This 2‐part study evaluated aficamten's impact on QTc interval in healthy participants. Part A (n = 10) was an open‐label study to find the appropriate dose...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Neha Maharao, Donghong Xu, Tyrell J. Simkins, Owen Bowles, Genzhou Liu, Youcef Benattia, Adrienne Griffith, Stephen B. Heitner, Stuart Kupfer, Polina German
Format: Artigo
Sprache:Inglês
Veröffentlicht: Wiley 2025-04-01
Schriftenreihe:Clinical and Translational Science
Schlagworte:
cardiovascular disease
phase 1
QT
QTc interval
safety
Online-Zugang:https://doi.org/10.1111/cts.70218
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge